Development of Naked DNA Vaccine: Brucella

Period of Performance: 05/25/1999 - 11/25/1999

$70K

Phase 1 SBIR

Recipient Firm

Nanodelivery, Inc.
Nashville, TN 37211
Principal Investigator

Research Topics

Abstract

This Phase I Proposal aims to maximize gene transfer by means of polymeric-based micellar and nanoparticulate delivery vehicles in order to elicit protective immunity against Brucella. In-vitro cell mediated cytotoxicity and in-vivo pathogen protection in a challenge test will be demonstrated. For Phase I Option we will further characterize the protective immunity by means of cellular and humoral responses and analyze the protective effect over an extended period of time. BENEFITS: Development of protective (and therapeutic) vaccine against Brucella as a commercial product